US EditionJardiance (Empagliflozin) Offers Cardiovascular and Renal Benefits Alongside Glycemic Control in Type 2 Diabetes - Gilmore Health News
Summary by Gilmore Health News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Jardiance (Empagliflozin) Offers Cardiovascular and Renal Benefits Alongside Glycemic Control in Type 2 Diabetes - Gilmore Health News
Key Takeaways Research has shown that Jardiance (Empagliflozin) was associated with fewer hospitalizations and deaths from cardiovascular causes. Furthermore, participants taking Jardiance achieved better glycemic control compared to placebo. It offers added protection for patients with heart failure or kidney disease. Diabetes is a chronic condition resulting from either an insufficient production of insulin by the pancreas or its inefficient u…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage